Lionaki Sophia, Skalioti Chrysanthi, Boletis John N
Sophia Lionaki, Chrysanthi Skalioti, John N Boletis, Nephrology Department and Transplantation Unit, Laiko Hospital, 11527 Athens, Greece.
World J Transplant. 2014 Sep 24;4(3):176-82. doi: 10.5500/wjt.v4.i3.176.
Despite improvements in overall prognosis in lupus nephritis, 10%-30% of patients with proliferative renal involvement progress to end stage renal disease, according to the severity of the disease and associated socioeconomic factors. Kidney transplantation has been recognized as the most appropriate treatment for those patients, but several issues remain after renal function restoration in a lupus recipient. Among these are the fear of lupus nephritis recurrence in the graft, the choice of immunosuppressive therapy in cases of recurrent lupus for a patient who has already received a toxic and prolonged immunosuppressive course, and finally, the management of comorbidities to reduce associated morbidities in the long term. All the above topics are examined in this review, with the hope of providing a clear picture of data as illustrated in the current literature.
尽管狼疮性肾炎的总体预后有所改善,但根据疾病的严重程度和相关社会经济因素,10%-30%的增殖性肾脏受累患者会进展至终末期肾病。肾移植已被认为是这些患者最合适的治疗方法,但狼疮患者肾功能恢复后仍存在几个问题。其中包括担心移植肾中狼疮性肾炎复发、对于已经接受了毒性大且疗程长的免疫抑制治疗的患者,复发性狼疮时免疫抑制治疗的选择,以及最后,如何管理合并症以长期降低相关发病率。本综述探讨了上述所有主题,希望能清晰呈现当前文献中的数据情况。